Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susana Maria Campos, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890. PMID: 36344654.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  2. Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 Jan 20; 41(3):599-608. PMID: 36174113.
    Citations: 1     Fields:    Translation:CTClinical Trials
  3. Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322. PMID: 35900726; PMCID: PMC9335244.
    Citations:    Fields:    
  4. Campos SM, Berlin S, Krasner CN, Whalen C, Atkinson T, Meegan K, Pereira L, Tyburski K, Lou W, Lee H, Horowitz N, Penson RT. A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol. 2022 03; 89(3):423-430. PMID: 35142863.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  5. Kolin DL, Konstantinopoulos PA, Campos SM, Toumi G, Kolahi KA, Gars EJ, Howitt BE. Vulvar Yolk Sac Tumors Are Somatically Derived SMARCB1 (INI-1)-Deficient Neoplasms. Am J Surg Pathol. 2022 02 01; 46(2):169-178. PMID: 34265804.
    Citations: 1     Fields:    Translation:HumansCells
  6. Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D'Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036. PMID: 34887522; PMCID: PMC8980096.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  7. Leung SOA, Foley O, Chapel D, Da Silva A, Nucci M, Muto MG, Campos S. Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain. Oncologist. 2021 12; 26(12):e2102-e2109. PMID: 34355460.
    Citations:    Fields:    Translation:Humans
  8. Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw. 2021 08 01; 19(8):888-895. PMID: 34416706.
    Citations: 11     Fields:    Translation:Humans
  9. Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666. PMID: 34243976.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539. PMID: 33705205.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  11. Schrier E, Xiong N, Thompson E, Poort H, Schumer S, Liu JF, Krasner C, Campos SM, Horowitz NS, Feltmate C, Konstantinopoulos PA, Dinardo MM, Tayob N, Matulonis UA, Patel M, Wright AA. Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586. PMID: 33637350.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  12. Do KT, O'Sullivan Coyne G, Hays JL, Supko JG, Liu SV, Beebe K, Neckers L, Trepel JB, Lee MJ, Smyth T, Gannon C, Hedglin J, Muzikansky A, Campos S, Lyons J, Ivy P, Doroshow JH, Chen AP, Shapiro GI. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 12; 86(6):815-827. PMID: 33095286.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  13. Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78. PMID: 32771276.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  14. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020 06; 18(6):660-666. PMID: 32502976.
    Citations: 47     Fields:    Translation:Humans
  15. Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584. PMID: 32265057.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  16. Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Wyse E, McMillian NR, Scavone J. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 11 01; 17(11):1374-1391. PMID: 31693991.
    Citations: 14     Fields:    Translation:Humans
  17. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377; PMCID: PMC9798913.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  18. Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101. PMID: 31118140.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  19. Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478. PMID: 30935717.
    Citations: 8     Fields:    Translation:Humans
  20. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 01; 17(1):64-84. PMID: 30659131.
    Citations: 209     Fields:    Translation:HumansCellsPHPublic Health
  21. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb; 16(2):170-199. PMID: 29439178.
    Citations: 155     Fields:    Translation:Humans
  22. Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA. Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316. PMID: 28917433.
    Citations:    Fields:    Translation:HumansPHPublic Health
  23. Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 01; 15(1):92-120. PMID: 28040721.
    Citations: 50     Fields:    Translation:Humans
  24. Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306. PMID: 27421044.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  25. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504. PMID: 26895621.
    Citations: 37     Fields:    Translation:Humans
  26. Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galvão VR, Berlin ST, Campos SM, Matulonis UA, Castells MC. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12. PMID: 26725998.
    Citations: 13     Fields:    Translation:Humans
  27. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2015 Nov; 13(11):1321-31. PMID: 26553763.
    Citations: 18     Fields:    Translation:Humans
  28. Matulonis U, Berlin S, Lee H, Whalen C, Obermayer E, Penson R, Liu J, Campos S, Krasner C, Horowitz N. Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23. PMID: 26119093.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  29. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Teng N, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):395-404; quiz 404. PMID: 25870376.
    Citations: 105     Fields:    Translation:Humans
  30. Worley MJ, Davis M, Berhie SH, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS, Campos SM. Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecol Oncol. 2014 Oct; 135(1):54-7. PMID: 25088333.
    Citations:    Fields:    Translation:Humans
  31. Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014 Jun; 133(3):537-41. PMID: 24594074; PMCID: PMC4360988.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  32. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M. Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw. 2014 Feb; 12(2):248-80. PMID: 24586086.
    Citations: 27     Fields:    Translation:Humans
  33. Dizon DS, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A. Pushing the bar in treatment of cervical cancer: what can comprehensive cancer centers do on their own? Gynecol Oncol. 2013 Nov; 131(2):464-6. PMID: 23938373.
    Citations: 2     Fields:    Translation:Humans
  34. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, Lurain JR, Martin L, Morgan MA, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Tillmanns T, Valea FA, McMillian NR, Hughes M. Cervical cancer. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):320-43. PMID: 23486458.
    Citations: 40     Fields:    Translation:Humans
  35. Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8. PMID: 23337490.
    Citations: 29     Fields:    Translation:Humans
  36. Campos SM, Doverspike L, Spinks M, Jacobson JO. Securing discharge follow-up appointments in a women's cancer program. J Clin Oncol. 2012 Dec; 30(34_suppl):81. PMID: 28147041.
    Citations:    
  37. Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S. A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20. PMID: 22885865.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  38. Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012 Oct; 127(1):51-4. PMID: 22659193.
    Citations: 7     Fields:    Translation:Humans
  39. Matulonis UA, Pereira L, Liu J, Lee H, Lee J, Whalen C, Campos S, Atkinson T, Hill M, Berlin S. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6. PMID: 22487536.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  40. Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin North Am. 2012 Jun; 26(3):607-28, viii-ix. PMID: 22520982.
    Citations: 5     Fields:    Translation:Humans
  41. Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1. PMID: 22366591.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  42. Campos SM, Berlin S, Matulonis UA, Muto MG, Pereira L, Mosquera MM, Horowitz N. Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401. PMID: 22747104.
    Citations: 5     Fields:    Translation:Humans
  43. Parithivel K, Jagannathan JP, Krajewski K, O'Regan K, Quick CM, Ramaiya N, Campos S. Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging. 2011 Jun 15; 11:67-9. PMID: 21684828.
    Citations: 2     Fields:    Translation:Humans
  44. Esselen KM, Rodriguez N, Horowitz NS, Campos SM. Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. J Clin Oncol. 2011 May 20; 29(15_suppl):5072. PMID: 28023665.
    Citations:    
  45. Viswanathan AN, Szymonifka J, Tanaka C, Berlin ST, Campos SM, Horowitz NS, Lee J, Whalen C, Matulonis U. The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101. PMID: 28019903.
    Citations:    
  46. Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, Dupont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical cancer. J Natl Compr Canc Netw. 2010 Dec; 8(12):1388-416. PMID: 21147903.
    Citations: 27     Fields:    Translation:Humans
  47. Partridge EE, Abu-Rustum NR, Campos SM, Fahey PJ, Farmer M, Garcia RL, Giuliano A, Jones HW, Lele SM, Lieberman RW, Massad SL, Morgan MA, Reynolds RK, Rhodes HE, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2010 Dec; 8(12):1358-86. PMID: 21147902.
    Citations: 15     Fields:    Translation:Humans
  48. Campos SM, Berlin ST, Parker LM, Chen WY, Bunnell CA, Atkinson T, Lee J, Matulonis U, Hirsch MS, Harris L, Krasner CN. Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8. PMID: 20405155.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  49. Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol. 2010; 2010:149362. PMID: 20069122.
    Citations: 20     
  50. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9. PMID: 19917843.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  51. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6. PMID: 19826113.
    Citations: 96     Fields:    Translation:HumansCTClinical Trials
  52. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9. PMID: 19481244.
    Citations: 35     Fields:    Translation:Humans
  53. Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7. PMID: 19433391.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  54. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, Cho KR, Copeland L, Crispens MA, Eifel PJ, Huh WK, Jaggernauth W, Kapp DS, Kavanagh JJ, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Alvarez Secord A, Small W, Teng N. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):498-531. PMID: 19460278.
    Citations: 11     Fields:    Translation:Humans
  55. Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44. PMID: 19299239.
    Citations: 14     Fields:    Translation:Humans
  56. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. PMID: 19047116.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  57. Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6. PMID: 19001330.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  58. Campos SM. Anti-epidermal growth factor receptor strategies for advanced breast cancer. Cancer Invest. 2008 Oct; 26(8):757-68. PMID: 18853311.
    Citations: 5     Fields:    Translation:Humans
  59. Cervantes A, Roselló S, Rodríguez-Braun E, Navarro S, Campos S, Hernández A, García-Granero E. Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 Sep; 19 Suppl 7:vii266-72. PMID: 18790964.
    Citations: 7     Fields:    Translation:Humans
  60. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80. PMID: 18502492.
    Citations: 101     Fields:    Translation:Humans
  61. Mirabeau-Beale K, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska LR, Pereira L, Gibson CD, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528. PMID: 27950848.
    Citations:    
  62. Castells MC, Tennant NM, Sloane DE, Hsu FI, Berlin ST, Campos SM, Matulonis UA. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526. PMID: 27950844.
    Citations:    
  63. Horowitz NS, Penson RT, Campos SM, Lee J, Kendall DL, Krasner CN, Berlin ST, Roche M, Duska LR, Matulonis UA. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523. PMID: 27950841.
    Citations:    
  64. N.S.Horowitz, R.T.Penson, S.M.Campos, J.Lee, D.L.Kendall, C.N.Krasner, S.T.Berlin, M.Roche, L.R.Duska, U.A.Matulonis. Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. 2008; 26(ASCO 2008):A: 5523.
  65. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Huh WK, Jaggernauth W, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan M, Morgan RJ, Powell CB, Remmenga SW, Reynolds RK, Secord AA, Small W, Teng N. Cervical cancer. J Natl Compr Canc Netw. 2008 Jan; 6(1):14-36. PMID: 18267056.
    Citations: 5     Fields:    Translation:Humans
  66. K.Mirabeale, A.B.Kornblith, R.T. Penson, H.Lee, A.Goodman, S.M.Campos, L.R.Duska, L.Pereira, C.D.Gibson, U.A.Matulonis. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. 2008; 26(ASCO 2008):A:5528.
  67. M.C.Castells, N.M.Tennant, D.E.Sloane, F.I.Hsu, S.T.Berlin, S.M.Campos, U.A.Matulonis. Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intervenous and intraperitoneal desensitizations in 413 cases. 2008; 26(ASCO 2008):A:5526.
  68. Partridge EE, Abu-Rustum N, Campos S, Fahey PJ, Greer BE, Lele SM, Lieberman RW, Lipscomb GH, Morgan M, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Teng N, Trimble CL, Valea F, Wilczynski S. Cervical cancer screening. J Natl Compr Canc Netw. 2008 Jan; 6(1):58-82. PMID: 18267060.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  69. Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007 Dec 17; 97(12):1618-24. PMID: 18000504; PMCID: PMC2360276.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  70. Cervantes A, Rodríguez-Braun E, Navarro S, Hernández A, Campos S, García-Granero E. Integrative decisions in rectal cancer. Ann Oncol. 2007 Jul; 18 Suppl 9:ix127-31. PMID: 17631565.
    Citations: 4     Fields:    Translation:Humans
  71. A.Viswanathan, N.Horick, C.Tanaka, S.Campos, U.Matulonis, R.Berkowitz. Chemotherapy and radiation therapy UPSC. 2007; 25(ASCO 2007):A:5535.
  72. S.M.Campos, D.S.Dizon, S.A.Cannistra, M.Roche, C.N.Krasner, S.T.Berlin, N.S.Horowitz, P. DiSilvestro, U.A.Matulonis, R.T.Penson. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarin and mullerian cancers. 2007; 25(ASCO 2007):A:5517.
  73. Cervantes A, Chirivella I, Rodriguez-Braun E, Campos S, Navarro S, García Granero E. A multimodality approach to localized rectal cancer. Ann Oncol. 2006 Sep; 17 Suppl 10:x129-34. PMID: 17018713.
    Citations: 5     Fields:    Translation:Humans
  74. Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV. Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80. PMID: 16806439.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  75. Campos SM, Parker L, Chen W, Bunnell CA, Atkinson T, Lee J, Matulonis UA, Harris LN, Krasner CN. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085. PMID: 27952379.
    Citations:    
  76. Penson RT, Cannistra SA, Seiden MV, Krasner CN, Matulonis UA, Horowitz NS, Berlin S, Dizon DS, Lee H, Campos SM. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020. PMID: 27952190.
    Citations:    
  77. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Jaggernauth W, Jhingran A, Kapp DS, Kavanagh J, Lipscomb GH, Lurain JR, Morgan RJ, Nag S, Partridge EE, Powell CB, Remmenga SW, Reynolds RK, Small W, Soper J, Teng N. Uterine cancers. J Natl Compr Canc Netw. 2006 May; 4(5):438-62. PMID: 16687093.
    Citations: 3     Fields:    Translation:Humans
  78. Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4. PMID: 16566993.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  79. R.T.Penson, S.A.Cannistra, M.V.Seiden, C.N.Krasner, U.A.Matulonis, N.S.Horowitz, S.T.Berlin, D.S.Dizon, H.Lee, S.M.Campos, n.representing members of the Dana-Farber Harvard Cancer Institute. Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced mullerian tumors. 2006; 24(ASCO 2006):A:5020.
  80. S.M.Campos, L.Parker, W.Chen, C.A.Bunnell, T.Atkinson, J.Lee, U.A.Matulonis, L.N.Harris, C.N. Krasner. Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractoy gynecological malignancies or metastatic breast cancer. 2006; 24(ASCO 2006):A:5085.
  81. Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41. PMID: 16343179.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  82. Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):807-16. PMID: 16316616.
    Citations: 3     Fields:    Translation:Humans
  83. Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C, Hirte H. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005 Aug 20; 23(24):5597-604. PMID: 16110019.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  84. Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9. PMID: 15986034; PMCID: PMC2361482.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  85. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6. PMID: 15958627.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  86. Penson RT, Krasner CN, Seiden MV, Atkinson T, Kornblith A, Campos S, Klein A, Matulonis U. Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159. PMID: 27946709.
    Citations:    
  87. Vukelja S, O'Shaughnessy J, Campos S, Vahdat L, Blum J, Yardley D, Mainwaring P, Senecal F, Benner R, Denis L, Perez E. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. J Clin Oncol. 2005 Jun; 23(16_suppl):562. PMID: 27946469.
    Citations:    
  88. Matulonis UA, Campos S, Krasner C, Duska L, Penson RP, Falke R, Roche M, Smith LM, Lee H, Seiden MV. A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010. PMID: 27946271.
    Citations:    
  89. Lee CW, Matulonis UA, Campos SM, Gross AH, Hayes CM, Keenan KT, Castells MC. Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090. PMID: 27947082.
    Citations:    
  90. U.A.Matulonis, S.M.Campos, C.Krasner, L.Duska, R.P.Penson, R.Falke, M.Roche, L.M.Smith, H.Lee, M.V.Seiden. A phase II trial of modified triple doublets for the treatment of advanced Mullerian malignancies. 2005; 23(ASCO 2005):A:5010.
  91. Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203. PMID: 15589601.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  92. Campos SM. Evolving treatment approaches for early breast cancer. Breast Cancer Res Treat. 2005; 89 Suppl 1:S1-7. PMID: 15770534.
    Citations:    Fields:    Translation:Humans
  93. C.Lee, U.A.Matulonis, S.M.Campos, A.H.Gross, C.M.Hayes, K.T.Keenan, M.C.Castells, . Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecological malignancies. 2005; 23(ASCO 2005):A:5090.
  94. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005 Jan; 96(1):10-8. PMID: 15589573.
    Citations: 19     Fields:    Translation:Humans
  95. R.T.Penson, C.N.Krasner, M.V.Seiden, T.Atkinson, S.M.Campos, A.Klein, U.Matulonis. Long-acting octreotide (Sandostatin LAR Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. 2005; 23(ASCO 2005):A:5191.
  96. S.Vukelija, J.O'Shaughnessy, S.M.Campos, L. Vahdat, J.Blum, D.Yardley, P.Mainwaring, F.Senecal, R.Benner, L.Denis, E.Perez. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results. 2005; 23(ASCO 2005):A:562.
  97. Teng N, Abu-Rustum NR, Bahador A, Bookman MA, Bristow RE, Campos S, Cho KR, Copeland L, Eifel P, Fiorica J, Greer BE, Kapp DS, Kavanagh J, Koh WJ, Kuettel M, Lurain JR, Molpus KL, Nag S, Partridge EE, Powell CB, Reynolds RK, Small W, Soper J, Tillmanns TD. Cervical cancer guidelines. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):612-30. PMID: 19780304.
    Citations: 2     Fields:    Translation:Humans
  98. Partridge EE, Abu-Rustum NR, Campos S, Edelson M, Fahey PJ, Fiorica J, Greer BE, Lieberman RW, Likes W, Molpus KL, Nava ME, Reynolds RK, Singh DK, Smith-McCune K, Soper J, Teng N, Trimble CL, Wilczynski S. Cervical cancer screening clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2004 Nov; 2(6):570-87. PMID: 19780301.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  99. Penson RT, Seiden MV, Campos SM, Krasner CN, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151. PMID: 28016790.
    Citations:    
  100. Cameron DA, Winer E, Campos S, Guastalla JP. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. J Clin Oncol. 2004 Jul 15; 22(14_suppl):628. PMID: 28016682.
    Citations:    
  101. Campos SM, Seiden MV, Oza A, Plante M, Potkul R, Hamid O, Lenehan P, Kaldjian E, Jordan C, Hirte H. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5054. PMID: 28015527.
    Citations:    
  102. Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM. Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7. PMID: 15196868.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  103. R.T. Penson, M.V.Seiden, S.M.Campos, C.N.Krasner, A.F.Fuller, A.Goodman, M.Roche, A.Willman, A.Muzikansky, U.A.Matulonis; Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase II study of fixed dose-rate gemcitabine in patients with relapsed Mullerian tumors. 2004; 22(ASCO 2004):A:5151.
  104. D.A. Cameron, E.Winer, S.C.Campos, J.-P. Guastalla; Western General Hospital, Edinburgh, United Kingdom; Dana-Farber, Boston,MA; Centre Leon Berard, Lyon, France. A comparative study of exemestane versus anastroxole in post-metopausal breast cancer subjects aith visceral disease. 2004; 22(ASCO 2004):A:628.
  105. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004; 9(2):126-36. PMID: 15047917.
    Citations: 20     Fields:    Translation:Humans
  106. S.M.Campos, M.V.Seiden, A.Oza, M.Plante, R.Potkul, O.Hamid, P.Lenehan, E.Kaldjian, C.Jordan, H.Hirte; Dana-Farber, Boston,MA; MAssachusetts General Hospital, Boston,MA; Princess Margaret, Toronto,ON, Canada; Pavilion L'Hotel-Dieu de Quebec, Quebec City, PQ, Canada; Loyola University Medical Center, Chicago IL; Pfizer, Inc, Ann Arbor, MI; Hamilton CAncer Center, Hamilton, ON, Canada. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. 2004; 22(ASCO 2004):A:5054.
  107. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602. PMID: 14675683.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  108. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8. PMID: 14599858.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  109. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95. PMID: 12885806.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  110. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist. 2003; 8 Suppl 2:10-6. PMID: 13679591.
    Citations: 6     Fields:    Translation:Humans
  111. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99. PMID: 12759523.
    Citations: 4     Fields:    Translation:Humans
  112. S.M.Campos; Dana-Farber Cancer institute, Boston,MA. Epoetin alfa 40,000 u once weekly significantly improves hemoglobin and quality of life in anemic patients with ovarian cancer. 2003; 22(ASCO 2003):A:3111.
  113. U.MAtulonis, S.C.Campos, M.Seiden, C.Krasner, A.Fuller, L.Duska, R.Berkowitz, T.Collela, A.Crowe, A.Goodman; Dana-FArber CAncer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA; Brigham and Women's Hospital, Boston,MA. Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. 2003; 22(ASCO 2003):A:1872.
  114. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10. PMID: 12217752.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  115. Campos S. The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol. 2002 Jun; 29(3 Suppl 8):7-12. PMID: 12082647.
    Citations: 3     Fields:    Translation:Humans
  116. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002 Mar 15; 20(6):1562-9. PMID: 11896105.
    Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
  117. R.T.Penson, J.P.Eder, A.F.Fuller, J.G.Supko, U.Matulonis, S.M.Campos, L.J.Appleman, M.Roche, A.Harris, M.V.Seiden, Massachusetts General Hospital, Boston,MA; Dana-Farber Cancer Institute, Boston,MA. A phase I trial of continual sequential oral etoposide and infusional topotecan. 2002; 21(ASCO2002):A:2168.
  118. M.O.Butler, M.Seiden, M.Mihm, S.M.Campos, L.Duska, D.Goldstein, A.Goodman, D.Neuberg, N.Nikrui, U.Matulonis, M.Muto, R.Penson, I.Webb, A.Fuller, R.Berkowitz, L.Nadler, G.Dranoff, Dana-Farber Cancer Institute,Boston,MA; Massachuesetts General Hospital,Boston,MA; Brigham and Women's Hospital,Boston,MA. A phase I of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). 2002; 21(ASCO 2002):A:1840.
  119. H.J.Burstein, P.K.Marcom, R.Lambert-Falls, K.Havlin, B.Overmoyer, R.J.Friedlander, C.H.Weissman, R.Strenger, C.L.Vogel, P.D.Ryan, M.J.Ellis, L.N.Harris, C.A.Bunnell, S.M.Campos, M.Hallor, E.P.Winer, Dana-Farber Cancer Institute, Boston,MA; Duke University Medical Center, Durham,NC; South Carolina Oncology Associates, West Columbia,SC; Evanston,IL; University Hospitals of Cleveland, Cleveland,OH; New Hampshire Oncology-Hematology, Hooksett,NH; US Oncology, Latham,NY; Miriam Hospital, Providence, RI; Columbia Cancer Research Network, Plantation, FL; Massachusetts General Hospital, Boston,MA. Multicenter phase II study of trastuzumab (Herceptin;H) and vinorelbine (Navelbine;N) as first-line therapy for HER2 overexpressing metastic breast cancer (HER2+MBC). 2002; 21(ASCO 2002):A:211.
  120. M.Theodoulou, S.M.Campos, G.Batist, E.Winer, L.Norton, C.Hudis, L.Welles, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; Jewish General Hospital, McGill University, Montreal, QC, Canada; Elan Pharmaceuticals, Pinceton,NJ. TLC D99 (D,Myocet) Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. 2002; 21(ASCO 2002):A:216.
  121. Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67. PMID: 11571729.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  122. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30. PMID: 11352965.
    Citations: 58     Fields:    Translation:HumansCTClinical Trials
  123. Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12. PMID: 11330951.
    Citations: 24     Fields:    Translation:Humans
  124. M.Theodoulou, S.M.Campos, L.Welles, G.Baptist, E.Winer, C.Hudis, Memorial Sloan-Kettering Cancer Center, New York,NY; Dana-Farber Cancer Institute, Boston,MA; The Liposome Company, Pinmceton, NJ; Jewish General Hospital (McGill Center for Translational Research), Montreal, Canada; Memorial-Sloan Kettering Cancer Center, New York, NY. Preliminary Cardiac Safety and Efficacy Data from Phase I/II Trial of TLC D-99 (D-99) and Trastuzumab (T) in patients withs locally advanced or Metastatic Breast CAncer (LABC/MBC). 2001; 20(ASCO 2001):A:180.
  125. S.M.Campos, R.T.Penson, U.A.Matulonis, R.S.Berkowitz, L.D.Duska, A.F.Fuller, A.K.Goodman, N.Nikrui, E.E.Sheets, M.Muto, K.M.MacNeill, J.C.Sivert, M.Roche, K.Wilson, J.G.Supko, M.V.Seiden, Dana-Farber Cancer Institute, Boston,MA; Massachusetts General Hospital, Boston,MA. A Phase II and Pharmacokinetic/Dynamic study of Doxil and weekly Paclitaxel chemotherapy for Rucurrent Mullerian Tumors. 2001; 20(ASCO 2001):A:2524.
  126. U.Matulonis, S.M.Campos, L.Duska, A.Fuller, R.Falke, S.Gore, R.Berkowitz, M.Roche, D.Finkelstein, J.Sivret, T.Colella, R.Penson, E.Sheets, M.Seiden, Dana-Farber/Partners Cancer Care, Boston,MA; Harvard Vanguard Medical Associates, Boston,MA. Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. 2001; 20(ASCO 2001):A:846.
  127. H.Burstein, I.Kuter, P.Richardson, S.M.CAmpos, L.Parker, U.Matulonis, L.Harris, J.GArber, J.Younger, C.Bunnell, L.Shulman, E.Winer. Herceptin and Vinorelbine for HER-2 Positive Metastatic Breast Cancer: A Phase II Study. 2000; 19(ASCO 2000):A:392.
  128. U.Matulonis, S.M.Campos, M.Seiden, A.Fuller, K.MacNeill, A.Charbonnier, R.Berkowitz, A.Goodman. Phase I Study Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. 2000; 19(ASCO 2000):A:1571.
  129. C.Bunnell, L.Parker, U.Matulonis, L.Shulman, A.Elias, L.HArris, R. Scheib, H.Burstein, S.M.Campos, J.Younger, I.Kuter, E.Winer. A Phase I Study Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. 2000; 19(ASCO 2000):A:444.
  130. A.Fuller, R.Penson, J.Supkp, U.Matulonis, R.Berkowitz, A.Goodman, S.Campos, K.MacNeill, K.Borden, S.Cook, S.Skates, M.Seiden. A Phase I/II Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recuurent Mullerian Tumors. 2000; 19(ASCO 2000):A:1552.
  131. S.M.Campos, R.Penson, U.Matulonis, R.Berkowitz, L.Duska, A.Fuller, A.Goodman, N.Nikrui, E.Sheets, M.Muto, K.MacNeill, C.Genovese. A Phase II and Pharmacokinetic/Dynamic Studyof Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Mullerian Tumors. 2000; 19(ASCO 2000):A:1623.
  132. Botella-Estrada R, Sammartín O, Martínez V, Campos S, Aliaga A. Magnetic resonance angiography in the diagnosis of a case of giant cell arteritis manifesting as scalp necrosis. Arch Dermatol. 1999 Jul; 135(7):769-71. PMID: 10411150.
    Citations: 1     Fields:    Translation:Humans
  133. S.M.Campos, R.Penson, K.MacNeill, R.Berkowitz, S.Cook, A.Fuller, A.Goodman, N.Najmosam, U.Matulonis, M.Seiden. A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer(ROC)(Meeting abstract). 1999; (ASCO 1999):A:1434.
  134. Campos SM, Walden T. Images in clinical medicine. Spigelian hernia. N Engl J Med. 1997 Apr 17; 336(16):1149. PMID: 9099659.
    Citations: 2     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Campos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (264)
Explore
_
Co-Authors (74)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.